Assessment of Circulating CCR6 Level in Acute Myocardial Infarction and its Association with Disease Severity.

Q2 Medicine Cardiovascular and Hematological Agents in Medicinal Chemistry Pub Date : 2023-01-01 DOI:10.2174/1871525721666230120160717

Amal Elmahdy Mohamed, Amira Mohamed Noureldin Abdelrahman, Ola Samir El-Shimi, Ahmed Mahmoud Bendary, Amira Adel Sedki

{"title":"Assessment of Circulating CCR6 Level in Acute Myocardial Infarction and its Association with Disease Severity.","authors":"Amal Elmahdy Mohamed, Amira Mohamed Noureldin Abdelrahman, Ola Samir El-Shimi, Ahmed Mahmoud Bendary, Amira Adel Sedki","doi":"10.2174/1871525721666230120160717","DOIUrl":null,"url":null,"abstract":"Background: Acute myocardial infarction (AMI) pathophysiology is mediated by systemic, intraplaque myocardial inflammatory processes that occur mainly due to coronary artery thrombosis in an atherosclerotic plaque area. The G-protein-coupled chemokine receptor (Ccr6) is displayed on the surface of many types of leukocytes, that have been found in atherosclerotic plaques. It is a novel mediator of inflammation and immune response.Objectives: To determine CCR6 lymphocyte expression in AMI patients and its association with disease severity using the Gensini scoring system.Methods: 25 AMI patients and 25 controls underwent flow cytometry to determine the percentage of circulating CCR6+ lymphocytes. To forecast AMI and determine how CCR6 expression relates to it, multivariate logistic regression analysis was used.Results and discussion: There was a higher percentage of CCR6+ lymphocyte expression in AMI patients than in controls. In addition, CCR6 showed a significant positive correlation with the Gensini score (GS) in the AMI group then with the degree of coronary artery disease (CAD).Conclusion: The chemokine receptor CCR6 is an independent biomarker for AMI and mayplay a role as a mediator of T lymphocyte recruitment, which is associated with coronary lesion destabilization.","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"21 3","pages":"223-231"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Agents in Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871525721666230120160717","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Acute myocardial infarction (AMI) pathophysiology is mediated by systemic, intraplaque myocardial inflammatory processes that occur mainly due to coronary artery thrombosis in an atherosclerotic plaque area. The G-protein-coupled chemokine receptor (Ccr6) is displayed on the surface of many types of leukocytes, that have been found in atherosclerotic plaques. It is a novel mediator of inflammation and immune response.

Objectives: To determine CCR6 lymphocyte expression in AMI patients and its association with disease severity using the Gensini scoring system.

Methods: 25 AMI patients and 25 controls underwent flow cytometry to determine the percentage of circulating CCR6+ lymphocytes. To forecast AMI and determine how CCR6 expression relates to it, multivariate logistic regression analysis was used.

Results and discussion: There was a higher percentage of CCR6+ lymphocyte expression in AMI patients than in controls. In addition, CCR6 showed a significant positive correlation with the Gensini score (GS) in the AMI group then with the degree of coronary artery disease (CAD).

Conclusion: The chemokine receptor CCR6 is an independent biomarker for AMI and mayplay a role as a mediator of T lymphocyte recruitment, which is associated with coronary lesion destabilization.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

急性心肌梗死患者循环CCR6水平的评估及其与疾病严重程度的关系

背景:急性心肌梗死(AMI)的病理生理是由系统性斑块内心肌炎症过程介导的，主要是由于动脉粥样硬化斑块区域的冠状动脉血栓形成。g蛋白偶联趋化因子受体(Ccr6)显示在许多类型的白细胞表面，已在动脉粥样硬化斑块中发现。它是一种新的炎症和免疫反应介质。目的:利用Gensini评分系统确定AMI患者CCR6淋巴细胞表达及其与疾病严重程度的关系。方法:25例AMI患者和25例对照者采用流式细胞术测定循环CCR6+淋巴细胞百分比。为了预测AMI并确定CCR6表达与AMI的关系，采用多变量logistic回归分析。结果与讨论:AMI患者CCR6+淋巴细胞表达比例高于对照组。CCR6与AMI组Gensini评分(GS)、冠状动脉病变程度(CAD)呈显著正相关。结论:趋化因子受体CCR6是AMI的独立生物标志物，可能是T淋巴细胞募集的中介，与冠状动脉病变不稳定有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular and Hematological Agents in Medicinal Chemistry Medicine-Cardiology and Cardiovascular Medicine

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Cardiovascular & Hematological Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Cardiovascular & Hematological medicinal chemistry. Cardiovascular & Hematological Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cardiovascular & hematological drug discovery.